[HTML][HTML] Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
B Jönsson, G Hampson, J Michaels, A Towse… - The European journal of …, 2019 - Springer
Background Advanced therapy medicinal products (ATMPs) are beginning to reach
European markets, and questions are being asked about their value for patients and how …
European markets, and questions are being asked about their value for patients and how …
[HTML][HTML] Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment
E Gonçalves - The European Journal of Health Economics, 2020 - Springer
Advanced therapy medicinal products (ATMPs) are a heterogeneous class of medicinal
products that by offering the potential of cure represent a paradigm shift in the approach of …
products that by offering the potential of cure represent a paradigm shift in the approach of …
[HTML][HTML] Value-based pricing for advanced therapy medicinal products: emerging affordability solutions
E Gonçalves - The European Journal of Health Economics, 2022 - Springer
The emergence of advanced therapy medicinal products (ATMPs), a disruptive class of
health technologies, is generating important challenges in terms of value assessment and …
health technologies, is generating important challenges in terms of value assessment and …
[HTML][HTML] Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European …
Background Although health technology assessment (HTA) systems base their decision
making process either on economic evaluations or comparative clinical benefit assessment …
making process either on economic evaluations or comparative clinical benefit assessment …
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
V Ronco, M Dilecce, E Lanati… - … Policy and Practice, 2021 - Taylor & Francis
Background Advanced therapy medicinal products (ATMPs) represent an important
cornerstone for innovation in healthcare. However, uncertainty on the value, the high …
cornerstone for innovation in healthcare. However, uncertainty on the value, the high …
Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?
Assessing the value of health technologies, through health technology assessment is
critically dependent on the existence of relevant and robust clinical data on the efficacy …
critically dependent on the existence of relevant and robust clinical data on the efficacy …
Proposal for a regulation on health technology assessment in Europe–opinions of policy makers, payers and academics from the field of HTA
P Vella Bonanno, A Bucsics, S Simoens… - Expert review of …, 2019 - Taylor & Francis
ABSTRACT Introduction: In January 2018 the European Commission published a Proposal
for a Regulation on Health Technology Assessment (HTA):'Proposal for a Regulation on …
for a Regulation on Health Technology Assessment (HTA):'Proposal for a Regulation on …
International regulations and recommendations for utility data for health technology assessment
D Rowen, I Azzabi Zouraq, H Chevrou-Severac… - …, 2017 - Springer
Recommendations and guidelines for the collection, generation, source and usage of utility
data for health technology assessment (HTA) vary across different countries, with no …
data for health technology assessment (HTA) vary across different countries, with no …
[HTML][HTML] Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
M Paulden - Expert review of pharmacoeconomics & outcomes …, 2017 - Taylor & Francis
Over recent years, the UKLs National Institute for Health and Care Excellence (NICE) has
implemented or proposed several amendments to its methods and processes for the …
implemented or proposed several amendments to its methods and processes for the …
[HTML][HTML] HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries
E Nicod, L Annemans, A Bucsics, A Lee, S Upadhyaya… - Health Policy, 2019 - Elsevier
Background Challenges commonly encountered in HTA of orphan medicinal products
(OMPs) were identified in Advance-HTA. Since then, new initiatives have been developed to …
(OMPs) were identified in Advance-HTA. Since then, new initiatives have been developed to …